bluuebunny/crossref_metadata_2025_split huggingface dataset:
Lab-Scale, Closed-Loop Experimental Characterization, Model Refinement, and Validation of a Hydrokinetic Energy-Harvesting Ocean Kite
Authors: Siddiqui Ayaz , Naik Kartik , Cobb Mitchell , Granlund Kenneth , Vermillion Chris 
Published: July 2020

Abstract
This paper presents a study wherein we experimentally characterize the dynamics and control system of a lab-scale ocean kite, and then refine, validate, and extrapolate this model for use in a full-scale system. Ocean kite systems, which harvest tidal and ocean current resources through high-efficiency cross-current motion, enable energy extraction with an order of magnitude less material (and cost) than stationary systems with the same rated power output. However, an ocean kite represents a nascent technology that is characterized by relatively complex dynamics and requires sophisticated control algorithms. In order to characterize the dynamics and control of ocean kite systems rapidly, at a relatively low cost, the authors have developed a lab-scale, closed-loop prototyping environment for characterizing tethered systems, whereby 3D printed systems are tethered and flown in a water channel environment. While this system has been shown to be capable of yielding similar dynamic characteristics to some full-scale systems, there are also fundamental limitations to the geometric scales and flow speeds within the water channel environment, making many other real-world scenarios impossible to replicate from the standpoint of dynamic similarity. To address these scenarios, we show how the lab-scale framework is used to refine and validate a scalable dynamic model of a tethered system, which can then be extrapolated to full-scale operation. In this work, we present an extensive case study of this model refinement, validation, and extrapolation on an ocean kite system intended for operation in the Gulf Stream or similar current environments.
Inverse Heat Transfer Study of a Power Transmission Line Tower Foundation
Authors: Zhang Daqian , Duan Xili 
Published: July 2020

Abstract
In some northern regions, power transmission lines are built with metal tower footings buried in the permafrost. With a high thermal conductivity, the tower footing has a significant thermal effect on the foundation and the nearby permafrost. Heat transfer models were previously developed to predict the thermal effect with line heat source assumptions, without knowing the exact spatial distribution and temporal variation of the heat source strength. This limited the accuracy of these heat transfer models. In this work, an inverse heat transfer method (IHTM) based on dynamic matrix control (DMC) theory is developed to better estimate the heat source strength representing the tower footing. The methodology is validated with numerical simulations and experimental data. It is found that the distribution of heat source varies spatially and temporally in a more complicated way than what was assumed in previous studies. The inversed heat source is then used to reconstruct the temperature fields in a tower foundation, which provides more accurate heat transfer analysis for design and maintenance of the foundation.
Effect of cumulative dexamethasone dose in preterm infants on neurodevelopmental and growth outcomes: a Western Australia experience
Authors: Buchiboyina Ashok Kumar , Yip Chi Seong Andrew , Kohan Rolland , Nathan Elizabeth A , Shrestha Damber , Davis Jonathon , Wang Xiaowei , Sharp Mary 
Published: July 2020

ObjectiveComparing the long-term neurodevelopmental and growth outcomes of lower and higher cumulative dexamethasone exposure in preterm infants ventilated for a minimum cumulative duration of 7 days.DesignA retrospective cohort medical chart review of infants born in Western Australia <29 weeks’ gestation between January 2007 and May 2016 who were mechanically ventilated >7 days.InterventionNo dexamethasone (controls) or a total cumulative dexamethasone dose of <2 mg/kg (lower) and ≥2 mg/kg (higher).Main outcome measuresLong-term disability at 2 and 5 years and growth measurement outcomes at 2 years of age.ResultsDexamethasone was given to 104 infants (66 with cumulative dose <2 mg/kg; 38 with cumulative dose ≥2 mg/kg), and 324 infants were controls. There was no difference in odds of long-term disability in infants with any dexamethasone exposure compared with controls (aOR: 0.90, 95% CI 0.34 to 2.02, p=0.784). No difference in long-term disability was found between the lower and higher groups (p=0.494). The prevalence of cerebral palsy (Gross Motor Functional Classification System level ≥2) between the control, lower and high-dose groups did not differ significantly (5.8% vs 4.0% vs 0%). The higher dose group had lower mean weight z-score (mean effect: −0.83, 95% CI: −1.54 to −0.01, p=0.023), height z-score (mean effect: −0.63, 95% CI: −12.5 to −0.01, p=0.048) and head circumference z-score (mean effect: −0.65, 95% CI: −1.25 to −0.05, p=0.035) compared with controls.ConclusionsIn our cohort, dexamethasone use was not associated with increased odds of long-term disability. Dexamethasone use was associated with lower growth measurements compared with controls.
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
Authors: Bagepally Bhavani Shankara , Chaikledkaew Usa , Gurav Yogesh Krishnarao , Anothaisintawee Thunyarat , Youngkong Sitaporn , Chaiyakunapruk Nathorn , McEvoy Mark , Attia John , Thakkinstian Ammarin 
Published: July 2020

ObjectivesTo conduct a systematic review and meta-analysis and to pool the incremental net benefits (INBs) of glucagon-like peptide 1 (GLP1) compared with other therapies in type 2 diabetes mellitus (T2DM) after metformin monotherapy failure.Research design and methodsThe study design is a systematic review and meta-analysis. We searched MEDLINE (via PubMed), Scopus and Tufts Registry for eligible cost–utility studies up to June 2018, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. We conducted a systematic review and pooled the INBs of GLP1s compared with other therapies in T2DM after metformin monotherapy failure. Various monetary units were converted to purchasing power parity, adjusted to 2017 US$. The INBs were calculated and then pooled across studies, stratified by level of country income; a random-effects model was used if heterogeneity was present, and a fixed-effects model if it was absent. Heterogeneity was assessed using Q test and I2statistic.ResultsA total of 56 studies were eligible, mainly from high-income countries (HICs). The pooled INBs of GLP1s compared with dipeptidyl peptidase-4 inhibitor (DPP4i) (n=10), sulfonylureas (n=6), thiazolidinedione (TZD) (n=3), and insulin (n=23) from HICs were US$4012.21 (95% CI US$−571.43 to US$8595.84, I2=0%), US$3857.34 (95% CI US$−7293.93 to US$15 008.61, I2=45.9%), US$37 577.74 (95% CI US$−649.02 to US$75 804.50, I2=92.4%) and US$14 062.42 (95% CI US$8168.69 to US$19 956.15, I2=86.4%), respectively. GLP1s were statistically significantly cost-effective compared with insulins, but not compared with DPP4i, sulfonylureas, and TZDs. Among GLP1s, liraglutide was more cost-effective compared with lixisenatide, but not compared with exenatide, with corresponding pooled INBs of US$4555.09 (95% CI US$3992.60 to US$5117.59, I2=0) and US$728.46 (95% CI US$−1436.14 to US$2893.07, I2=0), respectively.ConclusionGLP1 agonists are a cost-effective choice compared with insulins, but not compared with DPP4i, sulfonylureas and TZDs.PROSPERO registration numberCRD42018105193.
Survival and factors predicting mortality after major and minor lower-extremity amputations among patients with diabetes: a population-based study using health information systems
Authors: Cascini Silvia , Agabiti Nera , Davoli Marina , Uccioli Luigi , Meloni Marco , Giurato Laura , Marino Claudia , Bargagli Anna Maria 
Published: July 2020

IntroductionThe aim of the study was to identify the sociodemographic and clinical factors associated with death after the first lower-extremity amputation (LEA), minor and major separately, using data from regional health administrative databases.Research design and methodsWe carried out a population-based cohort study including patients with diabetes residing in the Lazio region and undergoing a primary amputation in the period 2012–2015. Each individual was followed up for at least 2 years. Kaplan-Meier analysis was used to evaluate long-term survival; Cox proportional regression models were applied to identify factors associated with all-cause mortality.ResultsThe cohort included 1053 patients, 72% were male, 63% aged ≥65 years, and 519 (49%) died by the end of follow-up. Mortality rates at 1 and 4 years were, respectively, 33% and 65% for major LEA and 18% and 45% for minor LEA. Significant risk factors for mortality were age ≥65, diabetes-related cardiovascular complications, and chronic renal disease for patients with minor LEA, and age ≥75 years, chronic renal disease and antidepressant drug consumption for subjects with major LEA.ConclusionsThe present study confirms the high mortality rates described in patients with diabetes after non-traumatic LEA. It shows differences between minor and major LEA in terms of mortality rates and related risk factors. The study highlights the role of depression as specific risk factor for death in patients with diabetes after major LEA and suggests including its definition and management in strategies to reduce the high mortality rate observed in this group of patients.
Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis
Authors: Petersen Jens Emil Vang , Kallemose Thomas , Barton Karen D , Caspi Avshalom , Rasmussen Line Jee Hartmann 
Published: July 2020

IntroductionChronic inflammation is increasingly recognised as a major contributor to disease, disability and ultimately death, but measuring the levels of chronic inflammation remains non-canonised, making it difficult to relate chronic inflammation and mortality. Soluble urokinase plasminogen activator receptor (suPAR), an emerging biomarker of chronic inflammation, has been proposed as a prognostic biomarker associated with future incidence of chronic disease and mortality in general as well as patient populations. Proper prognostic biomarkers are important as they can help improve risk stratification in clinical settings and provide guidance in treatment or lifestyle decisions as well as in the design of randomised trials. Here, we wish to summarise the evidence about the overall association of the biomarker suPAR with mortality in healthy, general and patient populations across diseases.Methods and analysisThe search will be conducted using Medline, Embase and Scopus databases from their inception to 03 June 2020 to identify studies investigating ‘suPAR’ and ‘mortality’. Observational studies and control groups from intervention studies written in English or Danish will be included. The ‘Quality In Prognosis Studies’ tool will be used to assess the risk of bias for the studies included. Unadjusted and adjusted mortality outcome measures (eg, risk ratios, ORs, HRs) with 95% CIs will be extracted for healthy individuals, general and patient populations. The primary outcome is all-cause mortality within any given follow-up. Subgroup analyses will be performed based on time of outcome, cause of death, population type, adjustments for conventional risk factors and inflammation markers.Ethics and disseminationThis systematic review will synthesise evidence on the use of suPAR as a prognostic marker for mortality. The results will be disseminated by publication in a peer-reviewed journal. Data used will be obtained from published studies, and ethics approval is therefore not necessary for this systematic review.Trial registration number PROSPEROCRD42020167401.
Implementation of health-focused interventions in vulnerable populations: protocol for a scoping review
Authors: Midboe Amanda M , Gray Caroline , Cheng Hannah , Okwara Leonore , Gale Randall C 
Published: July 2020

IntroductionVulnerable populations face significant challenges in navigating the care continuum, ranging from diagnosis of illness to linkage and retention in healthcare. Understanding how best to move individuals within these vulnerable populations across the care continuum is critical to improving their health. A large body of literature has focused on evaluation of implementation of various health-focused interventions in this population. However, we do not fully understand the unique challenges to implementing healthcare interventions for vulnerable populations. This study aims to examine the literature describing implementation of health service interventions among vulnerable populations to identify how implementations using the Consolidated Framework for Implementation Research are adapted. Findings from this review will be useful to implementation scientists to identify gaps in evidence and for adapting similar interventions in unique settings.Methods and analysisThis study protocol outlines a scoping review of the peer-reviewed and grey literature, using established approaches delineated in Arksey and O'Malley’s scoping review framework and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews Checklist. Search strategies will be developed and refined by a medical librarian in collaboration with the research team. Searches will be conducted in electronic databases (CINAHL, Cochrane, PsychINFO, PubMed, Social Services Abstracts, Web of Science, Google and Google Scholar) and limited to studies published between 1 August 2009 and 1 June 2020. Additionally, hand searches will be conducted in three relevant journals—Implementation Science, Systematic Reviews and BMJ Open. English-language studies and reports meeting inclusion criteria will be screened independently by two reviewers and the final list will be abstracted and charted in duplicate.Ethics and disseminationThis is a review of the literature; ethics approval is not indicated. We will disseminate findings from this study in peer-reviewed journals as well as presentations to relevant stakeholders and conferences.
Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review
Authors: Polhemus Ashley Marie , Bergquist Ronny , Bosch de Basea Magda , Brittain Gavin , Buttery Sara Catherine , Chynkiamis Nikolaos , dalla Costa Gloria , Delgado Ortiz Laura , Demeyer Heleen , Emmert Kirsten , Garcia Aymerich Judith , Gassner Heiko , Hansen Clint , Hopkinson Nicholas , Klucken Jochen , Kluge Felix , Koch Sarah , Leocani Letizia , Maetzler Walter , Micó-Amigo M Encarna , Mikolaizak A Stefanie , Piraino Paolo , Salis Francesca , Schlenstedt Christian , Schwickert Lars , Scott Kirsty , Sharrack Basil , Taraldsen Kristin , Troosters Thierry , Vereijken Beatrix , Vogiatzis Ioannis , Yarnall Alison , Mazza Claudia , Becker Clemens , Rochester Lynn , Puhan Milo Alan , Frei Anja 
Published: July 2020

IntroductionAdvances in wearable sensor technology now enable frequent, objective monitoring of real-world walking. Walking-related digital mobility outcomes (DMOs), such as real-world walking speed, have the potential to be more sensitive to mobility changes than traditional clinical assessments. However, it is not yet clear which DMOs are most suitable for formal validation. In this review, we will explore the evidence on discriminant ability, construct validity, prognostic value and responsiveness of walking-related DMOs in four disease areas: Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture.Methods and analysisArksey and O’Malley’s methodological framework for scoping reviews will guide study conduct. We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital Library and Cochrane Library) and grey literature for studies which (1) measure differences in DMOs between healthy and pathological walking, (2) assess relationships between DMOs and traditional clinical measures, (3) assess the prognostic value of DMOs and (4) use DMOs as endpoints in interventional clinical trials. Two reviewers will screen each abstract and full-text manuscript according to predefined eligibility criteria. We will then chart extracted data, map the literature, perform a narrative synthesis and identify gaps.Ethics and disseminationAs this review is limited to publicly available materials, it does not require ethical approval. This work is part of Mobilise-D, an Innovative Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain regulatory approval for DMOs. Results will be shared with the scientific community and general public in cooperation with the Mobilise-D communication team.RegistrationStudy materials and updates will be made available through the Center for Open Science’s OSFRegistry (https://osf.io/k7395).
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis
Authors: Rutter Matthew D , Brookes Matthew , Lee Thomas J , Rogers Peter , Sharp Linda 
Published: July 2020

ObjectiveThe COVID-19 pandemic has had a major global impact on endoscopic services. This reduced capacity, along with public reluctance to undergo endoscopy during the pandemic, might result in excess mortality from delayed cancer diagnosis. Using the UK’s National Endoscopy Database (NED), we performed the first national analysis of the impact of the pandemic on endoscopy services and endoscopic cancer diagnosis.DesignWe developed a NED COVID-19 module incorporating procedure-level data on all endoscopic procedures. Three periods were designated: pre-COVID (6 January 2020 to 15 March), transition (16–22 March) and COVID-impacted (23 March–31 May). National, regional and procedure-specific analyses were performed. The average weekly number of cancers, proportion of missing cancers and cancer detection rates were calculated.ResultsA weekly average of 35 478 endoscopy procedures were performed in the pre-COVID period. Activity in the COVID-impacted period reduced to 12% of pre-COVID levels; at its low point, activity was only 5%, recovering to 20% of pre-COVID activity by study end. Although more selective vetting significantly increased the per-procedure cancer detection rate (pre-COVID 1.91%; COVID-impacted 6.61%; p<0.001), the weekly number of cancers detected decreased by 58%. The proportion of missing cancers ranged from 19% (pancreatobiliary) to 72% (colorectal).ConclusionThis national analysis demonstrates the remarkable impact that the pandemic has had on endoscopic services, which has resulted in a substantial and concerning reduction in cancer detection. Major, urgent efforts are required to restore endoscopy capacity to prevent an impending cancer healthcare crisis.
Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
Authors: Wang Ya-Qin , Chen Lei , Mao Yan-Ping , Li Ying-Qing , Jiang Wei , Xu Shuo-Yu , Zhang Yu , Chen Yu-Pei , Li Xiao-Min , He Qing-Mei , He Shi-Wei , Yang Xiao-Jing , Lei Yuan , Zhao Yin , Yun Jing-Ping , Liu Na , Li Yingqin , Ma Jun 
Published: July 2020

BackgroundTumor-infiltrating lymphocytes have been reported as prognostic markers in tumors. We aimed to assess the prognostic value of total T cell (CD3+) density, cytotoxic T cell (CD8+) density and memory T cell (CD45RO+) density in patients with nasopharyngeal carcinoma (NPC).MethodsThe expression of CD3, CD8 and CD45RO was detected by immunohistochemistry in the training (n=221) and validation cohorts (n=115). The densities of these three markers were quantified by digital pathology both in the tumor and stroma. Then, we developed the immune score based on the density of these three markers and further analyzed its prognostic value.ResultsThe high density of CD3+, CD8+and CD45RO+T cells both in the tumor and/or stroma were significantly associated with the decrease in mortality in the training cohort, respectively. High immune score predicted a prolonged overall survival (OS) (HR 0.34, 95% CI 0.18 to 0.64, p=0.001, disease-free survival (DFS) (HR 0.44, 95% CI 0.25 to 0.78, p=0.005) and distant metastasis-free survival (DMFS) (HR 0.43, 95% CI 0.21 to 0.87, p=0.018) in NPC patients. The findings were confirmed in the validation cohort. Multivariate analysis revealed that immune score remained an independent prognostic indicator for OS, DFS and DMFS. In addition, we established a nomogram with the integration of all independent variables to predict individual risk of death.ConclusionsWe established an immune score model, which provides a reliable estimate of the risk of death, disease progress and distant metastasis in NPC patients.
Dietary intake, clinical-nutritional status, and homocysteine in hemodialysis subjects: the mediating role of inflammation (NUGE-HD study)
Authors: Balbino Karla Pereira , Juvanhol Leidjaira Lopes , Wendling Aline Lage , Marota Luciane Domingos , Costa Jaqueline Beatriz Silva , Bressan Josefina , Hermsdorff Helen Hermana Miranda 
Published: July 2020

The aim of the present study was to test the hypothesis that inflammation mediates the associations among food intake, clinical-nutritional status, and plasma homocysteine (Hcys) in hemodialysis (HD) subjects. This was a cross-sectional analysis of data on 129 subjects undergoing HD (58.9% male, 61.8 ± 15.5 years of age) from the cohort Nutrition and Genetics on HD outcomes (NUGE-HD study). Sociodemographic, anthropometric, and metabolic data were collected, and food intake was assessed using a quantitative food frequency questionnaire. Plasma C-reactive protein (CRP) was used as an inflammatory marker. Data were analyzed by structural equation modeling. Regarding the direct effects, complex B vitamin intake was negatively associated with body mass index, and diabetes mellitus was positively associated with CRP. Plasma CRP also showed a negative association with Hcys, and the ratio of saturated and polyunsaturated fatty acids intake showed a positive association with Hcys. Regarding indirect effects, the results showed that the relationship between the presence of diabetes mellitus and Hcys is mediated by plasma CRP. In conclusion, the ratio of saturated and polyunsaturated fatty acids had a direct effect on plasma Hcys, whereas inflammation had a direct and mediating effect on the relationship between Hcys and diabetes mellitus in HD subjects.Novelty In end-stage renal disease, CRP influences plasma Hcys directly and also indirectly through its mediating effect. The quantity and quality of dietary fatty acids influence plasma Hcys concentrations in HD subjects.